Research Analysts Set Expectations for ESPR FY2027 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities research analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a report released on Tuesday, March 25th. Zacks Research analyst K. Das expects that the biopharmaceutical company will post earnings of $0.06 per share for the year. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

A number of other research analysts have also recently weighed in on ESPR. JMP Securities reissued a “market outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Thursday, March 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price for the company. Finally, The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Stock Performance

Shares of ESPR stock opened at $1.63 on Thursday. The stock has a fifty day moving average price of $1.80 and a 200 day moving average price of $2.07. The stock has a market cap of $322.49 million, a PE ratio of -2.55 and a beta of 1.04. Esperion Therapeutics has a 1 year low of $1.47 and a 1 year high of $3.94.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ESPR. Wasatch Advisors LP increased its position in Esperion Therapeutics by 4.9% during the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock worth $53,861,000 after purchasing an additional 1,136,245 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Esperion Therapeutics by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after buying an additional 171,609 shares during the period. State Street Corp increased its holdings in shares of Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after buying an additional 99,802 shares during the last quarter. Two Sigma Advisers LP raised its position in shares of Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock worth $7,956,000 after buying an additional 16,100 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock valued at $6,862,000 after acquiring an additional 1,020,243 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.